ENTITY
NovaBridge Biosciences

NovaBridge Biosciences (NBP US)

68
Analysis
Health Care • China
NovaBridge Biosciences is a biopharmaceutical company. The Company specializes in discovery, development, and commercialization of novel biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. NovaBridge Biosciences operates globally.
more
•08 Jul 2020 15:10

I-Mab (å¤©å¢ƒē”Ÿē‰©) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry

I-Mab was listed in the USĀ  on Jan 17th and returned 96% since listing. I-Mab has a highly differentiated two segments of products, including...

Logo
472 Views
Share
bullish•Dada Nexus
•05 Jun 2020 13:09

Dada Nexus (达达集团) IPO Trading - Larger Deal Size with Decent Potential Upside

Dada Nexus (DADA US) raised US$336m at US$16 per share, the mid-point of its IPO price range. The number of ADS sold was upsized by about 27%, to...

Share
•17 Jan 2020 11:27

I-Mab (å¤©å¢ƒē”Ÿē‰©) IPO Trading: Tiny Float and Undemanding Valuation

I-Mab (IMAB US) raised USD 104 million at USD 14.0 per ADS, above the mid-point of the IPO price range. I-Mab will start trading today. We have...

Logo
642 Views
Share
bullish•Luckin Coffee
•12 Jan 2020 12:13

ECM Weekly (12 Jan 2020) - Jiumaojiu, I-Mab, Phoenix Tree, Burger King India

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. We are...

Share
•06 Jan 2020 18:06

I-Mab (å¤©å¢ƒē”Ÿē‰©) IPO: Everest Deal a Valuation Booster

I-Mab launched the book building to raise up to USD 111 million via a listing on NASDAQ.Ā In our previous notes, we covered the company’s key...

Logo
587 Views
Share
x